Fig. 3: FimH enhances OVA-specific T-cell immunity in mice in vivo.
From: Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
C57BL/6 mice were injected s.c. with 1 × 106 B16-OVA cells. Ten days after tumor-cell injection, CFSE-labeled OT-I and OT-II cells were transferred into the mice and subsequently treated with 2.5 mg per kg of OVA, 2.5 mg per kg of FimH, or a combination of OVA and FimH for 24 h. Tumor-draining lymph nodes (drLN) and tumors were harvested 3 days after treatment. a The proliferation of OT-I and OT-II T cells in the tumor-drLN of the CD45.1 congenic mice (left panel) and the mean percentages of the proliferating cells are shown (right panel). Division index (DI) was calculated by proliferation assay tool in flowjo software. (n = 6 mice, one-way ANOVA, mean ± SEM). b The absolute numbers of the tumor-infiltrating OT-I and OT-II cells. (n = 6 mice, one-way ANOVA, mean ± SEM). c The percentages of IFN-γ- and TNF-α-producing cells within the tumor-infiltrated OT-I and OT-II cells. d The mean percentages of IFN-γ- and e TNF-α-producing OT-I and OT-II cells are shown. (n = 6 mice, one-way ANOVA, mean ± SEM).
